Q&A with StockPal - Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX:NEU)
Share
Tweet
Watch Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX:NEU), speaking about Neuren’s area of drug focus and the latest updates on the Trofinetide development.
0:11– Firstly, can you tell us about the area of drug development that Neuren is focused on?
0:58– The syndromes you are treating occur in children. Could you tell us more about how they are affected by these diseases?
1:48– You have US partner ACADIA for Trofinetide – could you tell us the arrangement in this deal?
3:08– Can you tell us about the orphan drug status of your drugs and what are the benefits of this designation?
4:34– Results from the Phase 3 study of Trofinetide in Rett Syndrome are expected in the second half of this year. How is Neuren looking to capitalize on these results?
5:14– Neuren’s second drug NNZ-2591 is commencing a Phase 2 trials this year. How will the company fund such a broad clinical program?
5:47– Lastly, what are your top priorities for the year ahead and what key milestones do investors have to look forward to?
Visit Neuren’s website to learn more about their story:https://www.neurenpharma.com/
Email [email protected] if you are or represent a listed-company and is keen to be in our interviews.
Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com
The CEO Mindset - Dipra Ray, CEO of mPort and Springday
Dipra Ray is the CEO of mPort and Springday, the former being a health company specialising in 3D body mapping, to assist people on their wellbeing journeys while the latter is a corporate wellbeing organisation that develops bespoke programs for workplaces to keep their employees happy and engaged in their roles. The companies merged together at the end of 2019.
What’s your journey in becoming a Chief Executive Officer? I started my first business when I was in high school where I managed a network of really intelligent people who worked as tutors which gave me a strong foundation in being able to both hire and manage exceptional people. At university, I decided to pursue studies in Accounting and Finance as I thought would provide me with the base knowledge of how businesses operated and ended up completing an Honours in Finance. Post my Honours, I started my career as an investment banker with Deutsche Bank specialising in mergers and acquisitions. This gave me a broad base of commercial & capital markets knowledge and also the ability to work under high pressure environments. Post my stint at Deutsche, I founded mPort and was the first CEO there and have continued in that role since.
Tell us a bit about your business and how you are commercializing? mPort and Springday are building clever ecosystems that help to improve the wellbeing of people. At mPort we do this via capturing accurate body measurements through our one-of-a-kind fully automated mPods that are located in most of Australia’s top shopping centres. People use our service to see how their bodies are changing over time and to keep themselves motivated on their fitness journey. Springday on the other hand provides corporates with a platform to help keep their staff engaged, happier and healthier. We work with businesses to build wellbeing journeys that are personalised, interesting and fun. We work with some of Australia’s leading businesses who are committed to improve the wellbeing of their people.
What’s the most exciting thing about running your business? The most exciting part about running mPort & Springday is that we’re constantly growing and expanding both our products but also the range of industries and clients we service. Every week is an ability for us to continue building our product and create more value for our partners and customers. It’s also super exciting to see how we’ve been able to mature as a business and see the level of growth we’re generating for our own people.
How do you measure success? Success = being happy 🙂
What do you think is the most important quality of being a CEO of a listed company? The most important quality of being a CEO is to be able to set an achievable focused strategic vision and then focus ruthlessly on execution. Too many businesses set far too broad strategic visions or stumble when it comes to execution by getting distracted by anything new. Being disciplined and focused on one’s core strategies is really important for a high growth business.
What is your favourite book? Liar’s Poker by Michael Lewis and Five Point Someone by Chetan Bhagat.
What message do you want to send to our readership in Asia & Australia? Health and wellbeing will develop into a more sophisticated trend that what we’ve seen in the past few years. So far, the trend has been mainly focused on products such as health foods, dairy and alike. We’re seeing that shift as consumers become more aware of how important overall wellbeing is – both from an emotional and physical perspective. While emotional wellbeing still remains a taboo topic in a lot of Asian countries that will change as the younger generation demands better conditions and as the global workforce becomes more mobile. This is primarily why we see a huge opportunity to invest in wellbeing in the Asian markets.
How can people connect with you? Linkedin: https://www.linkedin.com/in/dipra-ray/ mPort’s Website: https://mport.com/ Springday’s Website: https://myspringday.com.au/
Q&A with StockPal - Dr. Daniel Tillett, Chief Scientific Officer (CSO) & Executive Director of Race Oncology (ASX:RAC)
Watch Dr. Daniel Tillett, Chief Scientific Officer (CSO) & Executive Director of Race Oncology (ASX:RAC), as he discusses the latest Israel AML Phase 2 Trial recently and the commencement of the Phase 2 Extramedullary AML Trial. 0:15 – Could you walk us through the latest announcement with regards to the Israel AML Phase 2 Trial Contract? 1:59 – Any reason for choosing Israel as the trial candidate, and which other countries were considered? 3:11 – When do you foresee Phase 3 to commence and what milestones must be achieved first? 5:16 – Lastly, could you also comment on the Phase 2 Extramedullary AML Trial commencement?
Visit RAC’s website to learn more about their story: https://www.raceoncology.com/
Email [email protected] if you are or represent a listed-company and is keen to be in our interviews.
Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com
Q&A with StockPal - Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1)
Watch Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1),as he explains about the Exopharm’s latest developments and potential target markets.
0:00– Intro
0:10– What is your business about?
1:20– Tell us about your product developments and pipeline?
3:01– What is the size of your potential target markets?
4:16– What is EX1’s competitive advantage?
5:30– How did your company cope during the COVID-19 pandemic?
6:28– How are you currently engaging with your investors?
Visit Exopharm’s website: https://exopharm.com/
Email [email protected] if you are or represent a listed-company and is keen to be in our interviews.
Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com